1. Гайдуль К.В., Гольдина И.А., Якимова Ю.Л. и др. Антибактериальные свойства цефотаксима, механически иммобилизованного на полимерном носителе // Якут. мед. журн. 2009. (2). 163–164.
2. Гайдуль К.В., Сафронова И.В., Гольдина И.А. и др. Исследование влияния модифицированного цефотаксима на функциональную активность лимфоцитов в культуре и на течение местного гнойно-септического процесса // Вестн. Урал. мед. акад. науки. 2010. (2-1). 246.
3. Душкин А.В. Возможности механохимической технологии органического синтеза и получения новых материалов // Химия в интересах устойчивого развития. 2004. (12). 251–274.
4. Любимов Г.Ю., Гольдина И.А., Гришина Л.В., Гайдуль К.В. Влияние масляного экстракта Curcuma longa L. на рост карциномы легких Льюис в эксперименте // Рос. иммунол. журн. 2014. (8). 702–704. [In Russian].
5. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies // Anticancer Res. 2003. 23. 363–398.
6. Aggrawal M.L., Chacko K.M., Kuruvilla B.T. Systematic and comprehensive investigation of the toxicity of curcuminoid-essential oil complex: A bioavailable turmeric formulation // Mol. Med. Rep. 2016. 13. 592–604.
7. Anand P., Runnumakkara A.B., Newman R.A., Aggrawal B.B. Bioavailability of curcumin: problems and promises // Mol. Pharm. 2007. 4. 807–818.
8. Anand P., Sundaram C., Jhurani S. et al. Curcumin and cancer: an «old-age» disease with an «age-old» solution // Cancer Lett. 2008. 267. (1). 133–164.
9. Antony B., Merina B., Lyer V.S. et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurumax) a novel bioenhanced preparation of curcumin // Indian J. Pharm. Sci. 2008. 70. 445–449.
10. Araujo C.A.C., Leon L.L. Biological activities of Curcuma longa L. // Mem. Inst. Oswaldo Cruz. 2001. 96. 723–728.
11. Bengmark S., Mesa M.D., Gil A. Plant-derived health – the effect of turmeric and curcuminoids // Nutr. Hosp. 2009. 24. 273–281.
12. Dhandapani K.M., Mahesh V.B., Brann D.W. Curcumin suppress growth and chemoresistence of human glioblastoma cells via AP-1 and NF-κB transcription factors // J. Neurochem. 2007. 102. 522–538.
13. Ferlay J, Shin H.R., Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 // Int. J. Cancer. 2008. 127. 2893–2917.
14. Ganesan P., Ko H.M., Kim I.S., Choi D.K. Recent trends in the development of nanophytobioactive compounds and delivery systems for their possible role in reducing oxidative stress in Parkinson’s disease models // Int. J. Nanomedicine. 2015. 10. 6757–6772.
15. Guo O., Li X., Yang Y. et al. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles // J. Biomed. Nanotechnol. 2014. 10. (2). 227–237.
16. Gupta S.C., Patchva S., Koh W., Aggrawal B.B. Discovery of curcumin, a component of golden spice, and its miraculous biological activities // Clin. Exp. Pharmacol. Physiol. 2010. 39. 283–299.
17. Huang W.Y., Cai Y.-Z., Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention // Nutrition and Cancer. 2010. 62. 1–20.
18. Khan N., Afaq F., Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth // Carcinogenesis. 2007. 28. 233–239.
19. Ramachandran C., Rodrigues S., Ramachandran R. et al. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and inflammatory epithelial cells lines // Anticancer Res. 2005. 25. 3293–3302.
20. Raz A., McLellan W.L., Hart I.R. et al. Cell surface properties of B16 melanoma variants with differing metastatic potential // Cancer Res. 1980. 40. 1645–1651.
21. Sasaki H., Sunagawa Y., Takahashi K. et al. Innovative preparation of curcumin for improved oral bioavailability // Biol. Pharm. Bull. 2011. 34. 660–665.
22. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy // Clin. Cancer Research. 2006. 12. 5268–5272.
23. Shankar S., Ganapathy S., Chen Q., Srivastava R.K. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis // Mol. Cancer. 2008. 7. ID 16.
24. Shin H.K., Kim J., Lee E.J. et al. Inhibitory effect of curcumin on motility of human oral squamosus carcinoma YD-10B cells via suppression of ERK and NF-κB activations // Phytother. Res. 2010. 24. 577–582.
25. Siegel R., Naishadham D., Jemal A. Cancer statistics 2012 // CA Cancer J. Clin. 2012. 62. 10–29.
26. Subbaramaiah K., Dannenberg A.J. Cyclooxigenase 2: a molecular target for cancer prevention and treatment // Trends. Pharmacol. Sci. 2003. 24. 96–102.
27. Yallapu M.M., Jaggi M., Chaahan S.C. Curcumin nanoformulations: a future nanomedicine for cancer // Drug Discov. Today. 2012. 17. 1–80.
28. Wang S., Su R., Nie S. et al. Application of nanotechnology in improving bioavailability and bioactivity of diet-derived phytochemicals // J. Nutr Biochem. 2014. 25. 363–376.
29. Zhang H., Grinstaff M.W. Recent advances in glycerol polymers: Chemistry and biomedical applications // Macromol. Rapid. Commun. 2014. 35. 1906–1924.
30. Zheng Y.Y., Viswanathan B., Kesarwani P., Mehrotra S. Dietary agents in cancer prevention: an immunological perspective // Photochem. Photobiol. 2012. 88. 1083–1098.
31. Zugic A., Jeremic I., Isakovic A. et al. Evaluation of anticancer and antioxidant activity of a commercially available CO2 supercritical extract of old man’s beard (Usnea barbata) // PLoS ONE. 2016. 11. ID e0146342.
